Data | Control subjects (n=16) | Patients with COPD (n=29) | Patients with COPD-PH (n=36) | P value |
Age (year) | 70.06±8.06 | 66.45±10.17 | 72.10±8.834 | 0.0751 |
Sex (male) | 7 (43.8%) | 25 (86.2%) | 32 (88.9%) | 0.001 |
Smoking (pack-year) | N/A | 30.0 (IQR: 5.5–49.5) | 37.5 (IQR: 12.5–58.0) | 0.3843 |
sPAP | N/A | N/A | 56.59±2.40 | N/A |
FEV1/FVC (%) | N/A | 47.09 (IQR: 39.07–62.34) | 41.77 (IQR: 35.13–57.95) | 0.3992 |
FVC/predicted value (%) | N/A | 63.40±21.84 | 65.39±22.97 | 0.8028 |
BNP (pg/mL) | N/A | 55.33 (IQR: 29.08–165.4) | 61.70 (IQR: 35.00–400.8) | 0.2848 |
CRP (mg/dL) | N/A | 0.65 (IQR: 0.40–8.60) | 1.01 (IQR: 0.615–2.315) | 0.9113 |
History | ||||
Hypertension | 0 | 14 (48.3%) | 14 (38.9%) | 0.463 |
Cardiovascular diseases | 0 | 6 (20.7%) | 4 (11.1%) | 0.321 |
Diabetes | 0 | 5 (17.2%) | 6 (16.7) | 1.000 |
Tumours | 0 | 1 (3.4%) | 2 (5.5%) | 1.000 |
Tuberculosis (past) | 0 | 2 (6.9%) | 3 (8.3%) | 1.000 |
BNP, B-type natriuretic peptide; CRP, C reactive protein; N/A, not available; PH, pulmonary hypertension; sPAP, systolic pulmonary artery pressure .